



Canadian
Cancer Clinical
Trials Network

Réseau canadien
d'essais cliniques
sur le cancer

Canadian Cancer Clinical Trials Network

3CTN Y7Q2 Performance Report

July 1, 2020 – September 30, 2020


Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials	2
Patient Recruitment at All Network Sites	2
Portfolio Trials and Accruals by Region/Site	3
Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – BC, Alberta and Manitoba.....	3
Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba.....	4
Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Ontario	5
Number of active recruiting 3CTN Portfolio trials – Ontario	6
Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Atlantic Region and Quebec	7
Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec	8
Section B: 3CTN Portfolio Metrics.....	9
Active Recruiting Portfolio Trials by Disease Site and Phase	9
Overview of Portfolio Applications – Process Efficiency.....	10
Trials Added to the 3CTN Portfolio in Y7 (Sept 23-Dec 13, 2020).....	11

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 75% within four years.



Notes:

- 3CTN network adult sites' Y7Q2 recruitment was more than 4 times that of Y7Q1 which almost put the network back on track to reaching the Y7 target.
- 1349 patients were recruited to Portfolio trials in Quarter 2 to bring the midyear total to 1703 patients. Y7 target is to achieve 65% above pre-3CTN baseline which would be 3917 patients recruited.
- Overall, ~21% of Adult Sites (9 out of 42) are on track to meet their Y7 target.
- * 1 Atlantic Region centre has not submitted a recruitment report for Y7.
- ** Pediatric progress to pre-3CTN baseline recruitment is shown. 3 Pediatric sites are on track to exceed their pre-3CTN baseline by end of Y7.

Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)				
							Q1	Q2	Total	% of Baseline	% to Target*
CancerCare Manitoba	99	72	102	90	98	51	3	8	11	11%	7%
Western Manitoba Cancer Centre	1	0	0	0	1	1	0	0	0	0%	0%
CancerCare Manitoba - Pediatrics	18	20	14	17	4	7	4	5	9	50%	-
Manitoba Total	118	92	116	107	103	59	7	13	20	17%	7%
BC Cancer – Vancouver	106	117	152	127	107	110	21	33	54	51%	31%
BC Cancer – Abbotsford	16	28	14	22	22	1	1	0	1	6%	4%
BC Cancer – Prince George	1	6	4	8	9	10	3	0	3	300%	182%
BC Cancer – Kelowna	38	40	30	28	38	33	12	13	25	66%	40%
BC Cancer – Victoria	26	44	69	64	69	78	4	19	23	88%	54%
British Columbia Total	187	235	269	249	245	232	41	65	106	57%	34%
Cross Cancer Institute	102	112	137	99	103	310	32	75	107	105%	64%
Tom Baker Cancer Centre	76	140	125	154	139	341	19	80	99	130%	79%
Alberta Total	178	252	262	253	242	651	51	155	206	116%	70%
Western Region Total	483	579	647	609	590	942	99	233	332	69%	42%

* Pediatric sites are excluded in provincial and regional “% to Y7 Target” calculations

Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)	
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
CancerCare Manitoba	37	28	27	29	23	22	19	16	22	13	20
Western Manitoba Cancer Centre	0	0	0	1	1	1	1	1	1	1	1
CancerCare Manitoba - Pediatrics	19	17	17	15	13	10	9	8	9	9	11
BC Cancer – Vancouver	50	25	25	27	27	26	25	23	27	16	17
BC Cancer – Abbotsford	6	4	4	4	4	5	5	0	0	1	1
BC Cancer – Prince George	2	3	3	3	3	2	2	3	3	4	5
BC Cancer – Kelowna	23	9	10	6	6	5	5	5	7	4	5
BC Cancer – Victoria	12	5	6	5	5	8	7	6	6	7	9
Cross Cancer Institute	29	29	28	30	29	27	26	27	21	14	25
Tom Baker Cancer Centre	20	29	32	32	30	30	34	33	33	28	28

Note: COVID-19 caused a majority of recruitment to open trials and new trial activations to be put on hold during Y7Q1; a majority of sites were able to resume trial operations in Y7Q2.

Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Ontario

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)				
							Q1	Q2	Total	% of Baseline	% to Target
London Health Sciences Centre	186	172	187	169	248	942	39	156	195	105%	64%
Grand River Regional Cancer Centre	20	13	43	32	34	19	9	5	14	70%	42%
Windsor Regional Cancer Centre	14	17	63	32	16	3	0	0	0	0%	0%
Juravinski Cancer Centre	181	231	247	454	345	217	16	32	48	27%	16%
Cambridge Memorial Hospital	11	2	5	4	5	8	3	4	7	64%	39%
St. Joseph's Healthcare Hamilton	21	30	54	74	40	20	6	6	12	57%	35%
Walker Family Cancer Centre	17	22	13	23	37	40	1	3	4	24%	14%
Sunnybrook Health Sciences Centre	141	229	398	363	651	638	33	67	100	71%	43%
Humber River Hospital	1	2	1	9	7	3	1	1	2	200%	121%
Michael Garron Hospital	2	2	1	7	2	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	384	533	473	720	543	14	61	75	19%	11%
Markham Stouffville Hospital	1	0	28	9	2	6	0	0	0	0%	0%
Mount Sinai Hospital	21	12	40	7	12	7	0	0	0	0%	0%
Northeast Cancer Centre	24	17	12	9	18	17	0	0	0	0%	0%
North York General Hospital	1	4	8	11	9	7	0	1	1	100%	61%
Royal Victoria Regional Health Centre	8	18	58	23	9	25	4	1	5	63%	38%
St. Michael's Hospital	19	0	27	2	1	3	0	0	0	0%	0%
Southlake Regional Health Centre	10	15	75	26	68	32	1	5	6	60%	36%
Thunder Bay Regional Health Sciences Centre	26	3	46	16	25	4	0	0	0	0%	0%
Trillium Health Partners - Credit Valley Hospital	27	5	51	10	12	10	0	0	0	0%	0%
William Osler Health System	1	0	29	13	0	16	0	0	0	0%	0%
The Ottawa Hospital Cancer Centre	132	238	396	500	850	804	62	127	189	143%	87%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	58	122	84	72	89	17	14	31	76%	46%
R.S. McLaughlin Durham Regional Cancer Centre	22	26	70	18	15	36	0	2	2	9%	6%
Central Region Total	1323	1500	2507	2368	3198	3489	206	485	691	52%	32%

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)	
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
London Health Sciences Centre	79	45	46	46	40	47	52	54	57	45	47
Grand River Regional Cancer Centre	11	8	8	8	8	6	7	8	8	8	8
Windsor Regional Cancer Centre	4	4	4	5	5	4	4	4	3	4	2
Juravinski Cancer Centre	51	29	27	30	32	22	26	24	34	13	31
Cambridge Memorial Hospital	5	2	2	3	2	2	2	2	2	2	2
St. Joseph's Healthcare Hamilton	2	3	2	2	3	1	1	1	1	1	1
Walker Family Cancer Centre	10	8	7	8	7	6	6	8	7	8	7
Sunnybrook Health Sciences Centre	10	32	34	34	35	34	36	36	35	47	35
Humber River Hospital	0	3	3	2	2	2	2	3	2	3	2
Michael Garron Hospital	3	2	2	2	2	1	1	1	1	1	1
Princess Margaret Cancer Centre	91	71	74	81	86	78	88	89	80	80	81
Markham Stouffville Hospital	0	0	0	1	1	1	0	1	1	1	1
Mount Sinai Hospital	6	4	4	4	4	4	5	6	3	3	2
Northeast Cancer Centre	10	6	7	7	8	7	7	7	7	8	7
North York General Hospital	0	3	4	3	3	3	5	4	1	2	3
Royal Victoria Regional Health Centre	5	8	6	6	6	6	6	9	10	10	9
St. Michael's Hospital	4	1	1	1	2	2	2	3	2	2	2
Southlake Regional Health Centre	3	9	10	10	10	9	8	8	7	6	6
Thunder Bay Regional Health Sciences Centre	8	5	5	5	5	5	5	4	3	0	0
Trillium Health Partners - Credit Valley Hospital	9	3	3	3	4	4	4	3	6	0	0
William Osler Health System	0	1	1	2	2	1	2	2	2	1	1
The Ottawa Hospital Cancer Centre	56	38	37	41	51	41	36	34	15	10	27
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	26	25	25	26	21	33	33	22	21	21
R.S. McLaughlin Durham Regional Cancer Centre	13	3	4	3	3	3	3	2	2	0	2

Note: COVID-19 caused a majority of recruitment to open trials and new trial activations to be put on hold during Y7Q1; a majority of sites were able to resume trial operations in Y7Q2.

Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)				
							Q1	Q2	Total	% of Baseline	% to Target*
Nova Scotia Health Authority	39	40	52	45	42	20	DNR	DNR	0	0%	0%
Eastern Regional Health Authority	15	4	12	8	15	16	0	0	0	0%	0%
Janeway Children's Health and Rehabilitation Centre	4	3	4	4	0	0	3	0	3	75%	-
Atlantic Total	58	47	68	57	57	36	3	0	3	5%	0%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	76	161	149	71	155	9	21	30	34%	21%
CISSS de l'Outaouais	3	0	4	32	1	5	0	0	0	0%	0%
CHU de Québec – Université Laval, adults	180	25	144	236	99	309	14	64	78	43%	26%
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	46	16	70	55	18	61	0	4	4	9%	5%
Centre Hospitalier de l'Université de Montréal (CHUM)	153	59	123	149	112	66	3	8	11	7%	4%
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	3	0	4	16	8	539	0	517	517	17233%	10444%
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	60	12	51	49	23	15	0	2	2	3%	2%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	14	7	17	22	21	8	3	11	65%	-
Centre hospitalier universitaire de Sainte-Justine	42	26	44	40	38	38	11	10	21	50%	-
Montreal Children's Hospital	24	23	14	20	8	10	1	4	5	21%	-
Quebec Total	615	251	622	763	400	1219	46	633	679	110%	78%
Eastern Region Total	673	298	690	820	457	1255	49	633	682	101%	66%

* Pediatric sites are excluded in provincial and regional “% to Y7 Target” calculations.

DNR= Did Not Report

Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec


Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)	
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Nova Scotia Health Authority	14	12	16	17	17	19	14	17	16	14	14
Eastern Regional Health Authority	6	4	6	5	6	8	9	10	9	0	6
Janeway Children's Health and Rehabilitation Centre	5	11	9	9	9	5	9	6	6	7	8
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	N/A	N/A	N/A	N/A	18	15	24	17	17	18
CISSS de l'Outaouais	1	1	1	1	2	2	2	2	2	2	1
CHU de Québec – Université Laval, adults	39	19	20	26	26	26	26	25	30	27	30
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	10	13	11	13	16	14	15	17	17	16	13
Centre Hospitalier de l'Université de Montréal (CHUM)	28	32	34	37	37	33	30	33	30	27	25
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	4	2	2	2	2	2	3	3	2	0	3
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	6	12	13	11	10	10	8	11	10	9	9
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	13	16	17	15	17	15	13	11	15	15
Centre hospitalier universitaire de Sainte-Justine	9	30	22	22	24	17	18	18	17	17	18
Montreal Children's Hospital	5	25	25	20	21	12	16	16	13	16	17

Note: COVID-19 caused a majority of recruitment to open trials and new trial activations to be put on hold during Y7Q1; a majority of sites were able to resume trial operations in Y7Q2.

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time.

Portfolio Approval Process Timeline¹

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2015	90	85	16	7
2016	70	71	31	6
2017	45	47	22	6
2018	46	44	18	5
2019	45	45	42	3
2020	40	36	27	0

Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed ²	Average FPR Time (days) ³	Median FPR Time (days) ³
2015	6	3	28	28
2016	11	12	76	62
2017	4	5	106	77
2018	10	7	86	74
2019	16	17	98	83
2020	7	6	137	134

¹ From application received to approve/decline the application for period, Jan 13, 2015 to Dec 13, 2020.

² Counts are based on the completed applications in that calendar year, e.g. for an application submitted for review in 2019 but completed the review process in 2020, the FPR time will be used for the 2020 calculation.

³ FPR process time is from the start date of peer review (i.e. site agreed to pursue peer review) to the date the last reviewer package is submitted to 3CTN (completed trials only).

Additional link to interactive Portfolio Application report: [Portfolio Applications Report](#)

Trials Added to the 3CTN Portfolio in Y7Q2 (July 1-Sept 30, 2020)

Trial short title	Trial phase	Disease site	Complexity rating	Canadian trial status	Trial link
(CCTG) IC.8	Phase III	Other	Low	Open to recruitment	NCT04442048
(CCTG) CX.6/ SENTICOL III	Not Applicable	Gynecological	Low	Open to recruitment	NCT03386734
(CCTG) ME.15 / MelMarT-II	Phase III	Skin / Melanoma	Low	Open to recruitment	NCT03860883
(COG) AALL1732	Phase III	Hematology	High	Open to recruitment	NCT03959085
(BCC) CARA/ H19-03343	Phase III	Breast	Low	Open to recruitment	NCT04257396
(GCAR) GBM AGILE	Phase II/III	Brain/CNS	Standard	Project in Setup	NCT03970447
(BCC) PROTRACT Study	Phase II	Genito-Urinary	Standard	Open, not yet recruiting	NCT04015622
(CCTG) IND.234G/PC-BETS Sub-Study G	Phase II	Genito-Urinary	Standard	Open to recruitment	NCT03385655 (G)

Additional link to interactive Portfolio trial listing: [3CTN's Portfolio Trial Listing](#)